The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia-Subanalysis of the DALI Study

Delia Bogdanet*, Miguel Angel Luque-Fernandez, Michelle Toth-Castillo, Gernot Desoye, Paula M O'Shea, Fidelma P Dunne, Jose A Halperin, The DALI Core Investigator Group, Peter Damm (Member of study group), Elisabeth Reinhardt Mathiesen (Member of study group)

*Corresponding author for this work

    Abstract

    CONTEXT: Neonatal hypoglycaemia (NH) is the most common metabolic problem in infants born of mothers with gestational diabetes. Plasma glycated CD59 (pGCD59) is an emerging biomarker that has shown potential in identifying women at risk of developing gestational diabetes. The aim of this study was to assess the association between early maternal levels of pGCD59 and NH.

    OBJECTIVE: The aim of this study was to assess the association between early pregnancy maternal levels of plasma glycated CD59 (pGCD59) and neonatal hypoglycemia (NH).

    METHODS: This is an observational study of pregnant women with a prepregnancy body mass index (BMI) greater than or equal to 29 screened for eligibility to participate in the Vitamin D and Lifestyle Intervention for Gestational Diabetes (DALI) trial. This analysis included 399 pregnancies. Levels of pGCD59 were measured in fasting maternal samples taken at the time of a 75-g, 2-hour oral glucose tolerance test performed in early pregnancy (< 20 weeks). NH, the study outcome, was defined as a heel-prick capillary glucose level of less than 2.6 mmol/L within 48 hours of delivery.

    RESULTS: We identified 30 infants with NH. Maternal levels of pGCD59 in early pregnancy were positively associated with the prevalence of NH (one-way analysis of variance, P < .001). The odds of NH were higher in infants from mothers in tertile 3 of pGCD59 levels compared to those from mothers in tertile 1 (odds ratio [OR]: 2.41; 95% CI, 1.03-5.63). However, this was attenuated when adjusted for maternal BMI (OR: 2.28; 95% CI, 0.96-5.43). The cross-validated area under the curve (AUC) was 0.64 (95% CI, 0.54-0.74), and adjusted for maternal BMI, age, and ethnicity, the AUC was 0.70 (95% CI, 0.56-0.78).

    CONCLUSION: Although pGCD59 levels in early pregnancy in women with BMI greater than or equal to 29 are associated with NH, our results indicate that this biomarker by itself is only a fair predictor of NH.

    Original languageEnglish
    JournalThe Journal of clinical endocrinology and metabolism
    Volume107
    Issue number11
    Pages (from-to)e4311-e4319
    ISSN0021-972X
    DOIs
    Publication statusPublished - 23 Nov 2022

    Keywords

    • Infant, Newborn
    • Infant
    • Female
    • Pregnancy
    • Humans
    • Diabetes, Gestational/epidemiology
    • Blood Glucose/metabolism
    • Glucose Tolerance Test
    • Hypoglycemia/epidemiology
    • Biomarkers/analysis
    • Infant, Newborn, Diseases
    • Fetal Diseases

    Fingerprint

    Dive into the research topics of 'The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia-Subanalysis of the DALI Study'. Together they form a unique fingerprint.

    Cite this